Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

BIOVIE INC.

BIVI · Nasdaq · CIK 0001580149 · Healthcare · Biotechnology

INSIDER SIGNAL

60.3 / 100

4 buyers · 4 purchase transaction lines · $49.1K gross purchase

WHY THIS SIGNAL?

Buyer breadthStrong
Purchase sizeLow
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+28.0 / 35
Purchase size+5.0 / 25
Role+13.0 / 20
Recency+4.3 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Role scores low · most senior buyer: President & CEO (CEO, chair and 10% owners score lowest)
  • ✓ Cluster breadth is broad · 4+ insiders

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Palumbo Joseph MChief Medical Officer
●
Chappell Amy SuzonDirector
●
KIM JOANNE WENDYChief Financial Officer
●
DO CUONG VPresident & CEO
●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS4
PURCHASE CONCENTRATION64%Largest buyer: DO CUONG V · $31.6K
CLUSTER BUYING · 15D4 insidersPeak activity: 2026-08-27–2026-08-28

Roles in the peak window: Chief Financial Officer, Chief Medical Officer, Director, President & CEO. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

60.3 / 100

Latest recorded score

↓ -0.2 ptsversus the previous recorded snapshot
  1. 60.9
  2. 60.7
  3. 60.6
  4. 60.5
  5. 60.3

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

4Purchases
0Sales
0Other Form 4 lines
4SEC filings · 365 days
BUYING4 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-27.2%
3M
-15.2%
6M
+3.0%
12M
-29.4%

Volatility & liquidity

Volatility
142.3%
Beta
—
Avg daily value
USD 6.5M

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
-214.9%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: ROE · Fiscal year ended: 2026-06-30 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
831,296
Previous report
1,046,014
Avg daily volume
304,924
Days to cover
2.7

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-28Palumbo Joseph MPurchase (P)Common Stock4,843USD 2.16USD 10,461SEC filing ↗
2026-08-28KIM JOANNE WENDYPurchase (P)Common Stock2,500USD 2.18USD 5,450SEC filing ↗
2026-08-28Chappell Amy SuzonPurchase (P)Common Stock727USD 2.16USD 1,570SEC filing ↗
2026-08-27DO CUONG VPurchase (P)Common Stock15,210USD 2.08USD 31,637SEC filing ↗
2025-08-07DO CUONG VPurchase (P)Common Stock5,000USD —USD —SEC filing ↗
2024-03-04DO CUONG VPurchase (P)Common stock10,000USD —USD —SEC filing ↗
2023-11-30DO CUONG VPurchase (P)Common stock10,000USD 1.78USD 17,800SEC filing ↗
2021-12-07KIM JOANNE WENDYPurchase (P)Class A common stock, par value $0.00012,000USD 5.40USD 10,800SEC filing ↗
2020-11-03GORLIN STEVEPurchase (P)Class A common stock, par value $0.00012,430USD 7.95USD 19,318SEC filing ↗
2020-10-30GORLIN STEVEPurchase (P)Class A common stock, par value $0.00012,570USD 7.97USD 20,483SEC filing ↗
2020-10-21GORLIN STEVEPurchase (P)Class A common stock, par value $0.00015,000USD 9.19USD 45,950SEC filing ↗
2020-10-15GORLIN STEVEPurchase (P)Class A common stock, par value $0.000115,100USD 10.10USD 152,517SEC filing ↗
2020-10-09GORLIN STEVEPurchase (P)Class A common stock, par value $0.0001282USD 9.61USD 2,710SEC filing ↗
2020-10-07GORLIN STEVEPurchase (P)Class A common stock, par value $0.00014,718USD 9.42USD 44,444SEC filing ↗
2020-09-22GORLIN STEVEPurchase (P)Class A common stock, par value $0.000115,000USD 10.00USD 150,000SEC filing ↗

Form 4 evidence

4 transaction lines in the latest 365-day window; 79 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-28Palumbo Joseph MPurchase (P)Common Stock4,843USD 2.16USD 10,461SEC filing ↗
2026-08-28KIM JOANNE WENDYPurchase (P)Common Stock2,500USD 2.18USD 5,450SEC filing ↗
2026-08-28Chappell Amy SuzonPurchase (P)Common Stock727USD 2.16USD 1,570SEC filing ↗
Show recent Form 4 evidence (4 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-28Palumbo Joseph MPurchase (P)Common Stock4,843USD 2.16USD 10,461SEC filing ↗
2026-08-28KIM JOANNE WENDYPurchase (P)Common Stock2,500USD 2.18USD 5,450SEC filing ↗
2026-08-28Chappell Amy SuzonPurchase (P)Common Stock727USD 2.16USD 1,570SEC filing ↗
2026-08-27DO CUONG VPurchase (P)Common Stock15,210USD 2.08USD 31,637SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerBIVI
CIK0001580149
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history79 transaction lines from 2020-01-02 to 2026-08-28
19 P purchase lines · 8 S sale lines · 52 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.